Table 6.
Total fatty acids of HBV cirrhosis patients in comparison of controls
| Fatty Acids (g/100 g) | Controls | Patients |
|---|---|---|
| C-14:0 | 1.00 ± 0.9 | 0.88 ± 0.7 |
| C-16 : 0 | 18.01 ± 4.0 | 24.54 ± 3.4* |
| C-18 : 0 | 16.00 ± 4.6 | 15.77 ± 3.4 |
| C-20 : 0 | 0.78 ± 0.6 | 0.21 ± 0.3* |
| C-24 : 0 | 0.02 ± 0.06 | 0.07 ± 0.2 |
| C-14 : 1 | 0.17 ± 0.4 | 0.26 ± 0.4 |
| C-16 : 1 | 2.03 ± 1.6 | 4.65 ± 0.7* |
| C-18 : 1 | 22.18 ± 4.8 | 23.70 ± 2.9 |
| C-22 : 1 | 1.75 ± 1.4 | 1.38 ± 0.9 |
| C-24 : 1 | 0.18 ± 0.5 | ND |
| C-18 : 2 | 28.72 ± 3.3 | 22.75 ± 3.2* |
| C-18 : 3 | 0.59 ± 0.9 | 0.12 ± 0.3 |
| C-20 : 3 | 1.35 ± 0.9 | 0.09 ± 0.1* |
| C-20 : 4 | 6.31 ± 1.0 | 3.57 ± 0.8* |
| C-20 : 5 | 0.71 ± 0.3 | ND* |
| C-22 : 5 | 0.33 ± 0.6 | 0.87 ± 0.8 |
| C-22 : 6 | 0.50 ± 0.6 | 0.51 ± 0.7 |
| C-16 : 1: C-16 : 0 | 0.1 | 0.2 |
| C-18 : 1: C-18 : 0 | 1.3 | 1.5 |
| PUFA : SFA | 1.5 | 0.6 |
Values are mean ± standard deviation,* shows significant difference from HBV-cirrhosis patients with comparison of healthy controls a p < 0.05 (t-test). myristic acid (C14:0), myristoleic acid (C14:1), palmitic acid (C16:0), palmitoleic acid (C16:1), stearic acid (C18:0), oleic acid (C18:1), linoleic acid (C18:2), α-linolenic acid (C18:3), arachidic acid (C20:0), eicosatrienoic acid (C-20:3), arachidonic acid (C20:4), eicosapentaenoic acid (EPA (C20:5), docosenoic acid (C22:1), docosahexaenoic acid (DHA (C22:6), nervonic acid(C24:1), not detected (ND)